iPSC-Derived Neural Progenitor Cells for Scalable GDNF Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like ALS are limited by the availability and variability of fetal tissue sources and the heterogeneity of lentiviral transduction methods, which hinder scalable and efficient production of GDNF-producing cells for engraftment in spinal cords.
Innovation Solution
Development of scalable, clinical-grade neural progenitor cell lines derived from human induced pluripotent stem cells (iPSCs) that can uniformly express GDNF using a clonal expansion approach and tetracycline-inducible promoter systems, ensuring safe and efficient engraftment in ALS rat models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fetal-derived neural progenitor cells are used for transplantation, then engraftment efficiency and neuroprotection are achieved, but scalability is limited by availability of starting material and expansion potential
Solution Approach 1:
The patent uses induced pluripotent stem cells (iPSCs) as a renewable copy source to replace limited fetal tissue. iPSCs can be generated from adult somatic cells and expanded indefinitely, providing an unlimited supply of neural progenitor cells for transplantation while maintaining the therapeutic efficacy of fetal-derived cells
2Reliability
If lentiviral transduction is used to induce GDNF expression, then GDNF production is achieved, but cellular heterogeneity increases with varying copy number and production levels
Solution Approach 1:
The patent extracts the GDNF transduction step from the lentiviral method and replaces it with direct genetic modification of iPSCs using integrating vectors. This allows uniform insertion of the GDNF gene into the genome of all cells in the population, eliminating the heterogeneity caused by variable lentiviral transduction efficiency and copy number variation
Solution Approach 2:
The patent changes the delivery mechanism parameter from lentiviral transduction to integrating vector transfection, which provides more uniform and predictable gene insertion. This parameter change results in consistent GDNF expression levels across the cell population while maintaining the ability to produce therapeutic GDNF protein
3Productivity
If fetal tissue sources are used, then neural progenitor cells for transplantation are obtained, but variability in cell quality and availability limits clinical scalability
Solution Approach 1:
The patent creates a universal cell production platform using iPSCs that can generate neural progenitor cells with consistent quality attributes. The iPSC-derived neural progenitor cells exhibit uniform expression of key markers (nestin, Sox1, Pax6) and can be produced in controlled laboratory conditions, eliminating the batch-to-batch variability inherent in fetal tissue sources
Data Source
AI summary
Described herein is the production neural progenitor cell lines (NPCs) derived from human induced pluripotent stem cells (iPSCs). These iPSC-derived NPCs engraft efficiently into the spinal cord of ALS animal models and provide neuroprotection to diseased motor neurons, similar to the fetal-derived cells used in clinical study. Clonal lines were generated with a single copy GDNF construct inserted in the AAVS1 safe landing site, including inducible expression of GDNF expression. These new iPSC-derived NPC lines are scalable to clinically relevant production volumes, uniformly produce GDNF, are safe, and represent a promising new combination therapy for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).